Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NATAZIA vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal half-life approximately 30 hours for drospirenone and 24 hours for ethinyl estradiol; steady-state achieved within 8–10 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Estetrol is metabolized primarily via glucuronidation (UGT1A1, UGT1A3, UGT1A9) and sulfation (SULT1E1). Drospirenone is metabolized via CYP3A4 and to a lesser extent by CYP1A1 and CYP2C9.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Fecal excretion is the primary route (approximately 68%), with renal excretion accounting for about 27% (mostly as metabolites).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Drospirenone: 95–97% bound to albumin (not to SHBG or CBG). Ethinyl estradiol: 98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Drospirenone: Vd approximately 0.7-1.0 L/kg. Ethinyl estradiol: Vd approximately 1.2-1.5 L/kg.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Drospirenone: absolute oral bioavailability approximately 76–85%. Ethinyl estradiol: oral bioavailability approximately 40–50% (first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
Contraindicated in patients with renal impairment (Cr Cl < 30 m L/min) due to risk of hyperkalemia. No dose adjustment required for mild to moderate impairment, but monitor serum potassium.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute liver disease or decompensated cirrhosis (Child-Pugh C). No dose adjustment for mild impairment (Child-Pugh A); use with caution in moderate impairment (Child-Pugh B) and monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Same as adult dosing for postmenarchal adolescents, but not indicated before menarche. Weight-based adjustments not established.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women; no specific dosing studies. In elderly with normal renal and hepatic function, standard dosing may be used, but consider increased risk of thromboembolism and cardiovascular events.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous and arterial),Cerebrovascular disease,Myocardial infarction,Breast cancer risk,Liver disease,Hypertension,Hyperkalemia (drospirenone component),Carbohydrate and lipid metabolism effects,Headache/migraine,Uterine bleeding irregularities,Depression
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Current or history of venous or arterial thrombosis,Cerebrovascular disease,Myocardial infarction or coronary artery disease,Breast cancer or other estrogen- or progestin-sensitive cancer,Liver tumors (benign or malignant) or active liver disease,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Renal impairment (creatinine clearance <30 m L/min),Adrenal insufficiency,Hypersensitivity to any component,Smoking and age ≥35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit and grapefruit juice may increase estrogen exposure and should be avoided. No other specific food interactions reported. Maintain a consistent diet to avoid variable contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy Category X. First trimester: high risk of severe fetal malformations including CNS, cardiovascular, and craniofacial defects (e.g., neural tube defects, cardiac septal defects). Second and third trimesters: increased risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment due to direct fetal toxicity.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Contraindicated during breastfeeding. No human data on M/P ratio; animal studies indicate significant excretion into milk with potential for severe adverse effects including growth retardation and renal toxicity in nursing infants.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; contraindicated in pregnancy. If inadvertent exposure occurs, discontinue immediately; no dose adjustment is recommended as the drug should be avoided entirely.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
NATAZIA (estradiol valerate/dienogest) is a four-phasic oral contraceptive. It is contraindicated in women with hepatic impairment, active liver disease, or a history of liver tumors. Due to the progestin dienogest, it may have antiandrogenic effects, beneficial for acne or hirsutism. Missed pills require specific instructions due to the dynamic dosing schedule; use a backup method if pills are missed during the first week.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take the pills in the exact order on the blister pack, starting with the first pill on the first day of your menstrual period.,Swallow the tablet whole with some liquid, with or without food.,If you vomit or have severe diarrhea within 3-4 hours of taking a pill, it may not be fully absorbed; consider it as a missed pill.,You may not have a withdrawal bleed every month; if you miss two withdrawal bleeds in a row, check for pregnancy.,NATAZIA does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NATAZIA vs AFIRMELLE, answered by our medical review team.
NATAZIA is a Oral Contraceptive that works by Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NATAZIA and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NATAZIA is: Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NATAZIA and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NATAZIA is classified as Category C. Pregnancy Category X. First trimester: high risk of severe fetal malformations including CNS, cardiovascular, and craniofacial defects (e.g., neural tube defects, cardiac septal de. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.